Cancer of Stomach Clinical Trial
Official title:
Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy
The aim of our study was to demonstrate the efficacy and feasibility of the medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy.
Status | Recruiting |
Enrollment | 10000 |
Est. completion date | March 1, 2020 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - asymptomatic subjects undergong magnetically controlled capsule gastroscopy for health checkup in medical consotium; - subjects able to give informed consent Exclusion Criteria: - suspected or known intestinal stenosis, obstruction, or fistula; - inoperability of refusal to accept any abdominal surgery; - dysphagia or gastric paralysis; - previous history of gastrointestinal disease; - with pacemaker, implanted-cardiac defibrillator or other implanted electromedical devices; - need for standard magnetic resonance imaging examination within seven days after swallowing the MCCG, unless the capsule is confirmed to have been excreted; - other factors that are not suitable for inclusion evaluated by medical stuff |
Country | Name | City | State |
---|---|---|---|
China | Department of Gastroenterology, Qilu Hospital, Shandong University | Jinan | Shandong |
Lead Sponsor | Collaborator |
---|---|
Yanqing Li |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | adverse events | safety assessment | 12 months | |
Primary | the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer. | 12 months | ||
Secondary | tthe focal lesions of upper gastrointestinal tract | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00164918 -
Role of Routine Nasogastric Decompression After Subtotal Gastrectomy
|
Phase 3 | |
Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
Completed |
NCT05088304 -
GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
|
||
Active, not recruiting |
NCT00164892 -
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial
|
Phase 3 | |
Active, not recruiting |
NCT00165048 -
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial
|
Phase 3 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03468712 -
Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
|
N/A | |
Recruiting |
NCT03301493 -
Genomic Testing and Resulting Medical Decisions
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Completed |
NCT01614522 -
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
|
Phase 2 | |
Completed |
NCT02374255 -
Improving Goals of Care Discussion in Advanced Cancer Patients
|
N/A | |
Recruiting |
NCT05804331 -
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
|
||
Active, not recruiting |
NCT03775525 -
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04270890 -
Investigation of an Abdominal Compression Device
|
N/A | |
Recruiting |
NCT02486601 -
NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05041335 -
Wet Heparinized Suction for Abdominal Cancer
|
N/A | |
Completed |
NCT03541629 -
Audit of the Spanish EURECCA Esophagogastric Cancer Registry
|
||
Completed |
NCT03102229 -
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
|
N/A | |
Not yet recruiting |
NCT05747482 -
Omentectomy vs Omental Preservation in Resectable Cancer
|
N/A |